Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 mcg and 100 mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.
NCT01689337 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 mcg and 100 mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.
- Lead sponsor
- EMD Serono
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2013
- Completion date
- October 31, 2013
- Enrollment
- 1 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cartilage injury of knee